Telix Pharmaceuticals Ltd balance sheet

At the end of fiscal 2025, Telix Pharmaceuticals Ltd had total assets of $1.16bn, total liabilities of $749m and shareholders' equity of $415m. It held $142m in cash against $405m of debt: net debt of $263m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Telix Pharmaceuticals Ltd: balance sheet, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025
Cash and equivalents	84	440	142
Receivables	44	87	129
Inventory	13	24	37
Total current assets	159	570	330
Goodwill	—	67	199
Total assets	277	940	1,164
Total current liabilities	111	205	232
Short-term debt	1	23	25
Long-term debt	6	675	775
Total debt	7	354	405
Total liabilities	175	587	749
Shareholders' equity	103	353	415
Net debt (negative = net cash)	−78	−86	263

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: TGTX vs TLX ASND vs TLX IONS vs TLX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Telix Pharmaceuticals Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Telix Pharmaceuticals Ltd.